Keytruda approved as 1st-line treatment for gastric cancer
By Son, Hyung-Min | translator Alice Kang
24.01.16 17:13:56
가나다라
0
On the 16th, MSD held press conference to announce the approval of Keytruda as a first-line treatment for gastric cancer
Efficacy of Keytruda plus chemotherapy has been confirmed in clinical trials enrolling patients with HER2-positive gastric cancer
The challenge lies in verifying the PL-L1 expression in HER2-postive patients, underscoring the importance of dual diagnosis
▲Sun Young Rha, Professor in the Department of Oncology at Younsei Cancer Center
Keytruda, a cancer immunotherapy developed by MSD, has been approved as a first-line treatment for gastric cancer in Korea. Keytruda has emerged as a new first-line treatment option, thirteen years after Herceptin (ingredient: trastuzumab) received approval in 2010.
On the 16th, MSD hosted a press conference at Lotte Hotel Seoul commencing expanded indication for Keytruda (pembrolizumab) as a first-line treatment for HER2-positive gastric cancer.
In December last year, Keytruda received expanded approval for use in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment for patients diagnosed with locally advanced unresectabl
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)